Previous 10 | Next 10 |
Once again the FDA has shown that when it comes to new therapies for diabetes, particularly Type 1 diabetes, the agency believes in an abundance (perhaps an overabundance) of caution. To that point, Sanofi ( SNY ) and Lexicon ( LXRX ) announced on Friday March 22 that the FDA rejected ...
THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday, March 22, 2019, at 2:45 p.m. EDT (1:45 p.m. CDT) to provide a regulatory update on sotaglifl...
PARIS and THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista™ (sotagliflozin)*, a dual SGLT1 and SGLT2 inhibitor for the tre...
Nasdaq has suspended trading in Lexicon Pharmaceuticals ( LXRX -5.3% ) pending the release of news, a near-certainty that it pertains to the expected FDA nod for Sanofi's ( SNY -2.6% ) oral Zynquista (sotagliflozin) for type 1 diabetes. Today is the agency's action date. More news on: ...
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securiti...
Motif Bio plc (NASDAQ: MTFB ) +55% on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...
Gainers: SMAR +11.5% . SCS +6.9% . TRN +4.6% . SUPV +3.8% . LXRX +2.8% . More news on: Smartsheet Inc., Steelcase Inc., Trinity Industries, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals ( LXRX +3.8% ) is up on below-average volume in reaction to its announcement that the first patient has been dosed in a Phase 2a clinical trial, TELE-ABC , evaluating XERMELO (telotristat ethyl) in patients with biliary tract cancer. More news on: Lexicon Pha...
THE WOODLANDS, Texas, March 15, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Tel otristat E thyl for A dvanced B iliary Tract C ancer, or TELE-ABC, study, which is a Phase 2a clinical study of telotristat ...
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...